RxDoctor Payments Data

Preethi Durgam, DO

Neurology · Tomball, TXNPI 1982929253

Payments from drug & device makers

$24,161in general payments, 2019–2025

Across 407 payments — averaging $59.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$9K
  • EMD Serono, Inc.$6K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Inspire Medical Systems, Inc.$831
  • AbbVie$620
  • Novartis$539
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,66198%
  • Education$1252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$24,161 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$275,959
Medicare patients
534
Services billed
1,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate41$339,495
TecfideraDimethyl Fumarate12$113,338
CopaxoneGlatiramer Acetate13$74,599
AptiomEslicarbazepine Acetate19$58,397
QuliptaAtogepant25$29,085
UbrelvyUbrogepant16$24,253
Aimovig AutoinjectorErenumab-Aooe18$24,085
Lacosamide131$18,249
Nurtec OdtRimegepant Sulfate15$17,418
NayzilamMidazolam15$14,217
Memantine Hcl395$11,117
Oxcarbazepine49$7,195
Levetiracetam130$5,789
Divalproex Sodium209$5,761
RivastigmineRivastigmine Tartrate47$5,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$471$339,49541 claims
BiogenTecfidera$215$113,33812 claims
Teva Pharmaceuticals USA, Inc.Copaxone$2,102$74,59913 claims
Sunovion Pharmaceuticals Inc.Aptiom$28$58,39719 claims
AbbVieQulipta, Ubrelvy$620$53,33941 claims
PfizerNurtec Odt$291$17,41815 claims
UCB, Inc.Nayzilam$63$14,21715 claims
Avion PharmaceuticalsDhivy$45$89112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →